A medical imaging company providing technology solutions to improve treatment for people with coronary artery disease, SpectraWAVE, Inc., has secured $50 million in Series B funding round to support commercial expansion and the addition of new products.
Co-founded in 2017 by Guillermo Tearney, and Gregg Stone, SpectraWAVE has developed an intravascular imaging technology, HyperVue™ Imaging System, which leverages photonics to improve the outcomes for coronary artery disease patients.
The round was spearheaded by Johnson & Johnson Innovation – JJDC, Inc., with notable contributions from Lumira Ventures, S3 Ventures, Deerfield Management, SV Health Investors, Heartwork Capital and NovaVenture, alongside other undisclosed angel investors.
SpectraWAVE’s HyperVue
Intravascular imaging is critical for providing key insight into plaque morphology, modification decisions, landing zone selection, stent, and balloon sizing, confirmation of treatment and optimization, and adverse risks in the future.
The imaging technology helps clinicians optimize coronary stenting procedures while also allowing for compromises in image qualities such as depth and resolution. Focusing on improving patient outcomes, Spectra WAVE has developed an innovative technology to simplify workflow for clinicians.
The company’s HyperVue is the first intravascular medical imaging technology to combine the power and effectiveness of DeepOCT and NIRS, two vital imaging technologies offering comprehensive image analysis and AI-driven workflow.
Eman Namati, Chief Executive Officer of SpectraWAVE, said in a statement that the company was working on wire-free physiology add-on software that would allow physicians to use rapid tests to check for pressure drops in the coronaries using HyperVue hardware.
